Video Commentary: Why The Sanofi Partnership Is Favorable For MannKind

Summary. The Sanofi deal with MannKind is actually favorable for Afrezza because Sanofi already has the world-class sales and marketing infrastructure for Lantus, the top selling basal insulin. Sanofi can just now tag Afrezza along, which will speed up the launch for Afrezza as well as cutting down cost (SGA). It is better to receive a smaller percentage or 35 of the 35/65 profit split of a huge blockbuster rather than a larger percentage of a much smaller pie.  Readers can access the full research article on the Sanofi-MannKind Partnership via this link MannKind Corporation: How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug.

Read more at Retail Investor 360.

Disclosure: We are long on MannKind, and we do not have financial relationship with any company we cover. We initially recommended MannKind to friends and relatives at the share ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.